Chinese Simcere Reports Fourth Quarter Sales Growth; Preparing For Health Care Reforms
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China-based Simcere Pharmaceutical Group reported a spike in the sales of its two main products, anti-cancer drug Endu and injectable edaravone Bicun in its fourth quarter 2007 financial results.
You may also be interested in...
CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight
BEIJING - One of China's leading drug makers, Simcere Pharmaceutical Group, is set to speed up its expansion through a series of acquisitions throughout 2008
CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight
BEIJING - One of China's leading drug makers, Simcere Pharmaceutical Group, is set to speed up its expansion through a series of acquisitions throughout 2008
Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28